Intellectual Property News & Topics - Secerna LLP

VENCLEXTA®

A to Z: Drugs in Highlight: V is for VENCLEXTA®

News A to Z Feature 30/04/2025

Our A to Z series highlights VENCLEXTA® (venetoclax) from AbbVie, a medication used to treat both chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML). This article explores its mechanism of action, clinical applications, and the patent protection surrounding this important drug.

Read more

JBOAKES - Secerna

Events, News, Team news 07/04/2025

Jason Boakes will be in San Diego (17th - 22nd May)

REXULTI

News, A to Z Feature 03/04/2025

A to Z: Drugs in Highlight: R is for REXULTI®

LAOS EPO

European, News 03/04/2025

European Patent Validation in Laos

YNYCA (1)

Events, News, Team news 01/04/2025

Webinar: Why does Intellectual Property matter to your business?

QUVIVIQ (1)

News, A to Z Feature 27/03/2025

A to Z: Drugs in Highlight: Q is for QUVIVIQ®

Trade Mark 'Genericide' The Double Edged Sword Of Success (1)

News 24/03/2025

Trade mark 'genericide': the double-edged sword of success

PAXLOVID

News, A to Z Feature 19/03/2025

A to Z: Drugs in Highlight: P is for PAXLOVID®

Secerna Website Images 2025 (8)

News, Team news, Careers 19/03/2025

Join Our Growing Team: Part-Qualified Patent Attorney, Physics & Engineering

Trademark Canva

Industry news, News 18/03/2025

Global IP Filings Show Strengthening: WIPO Report Signals Innovation Growth

1 2 3 4 5 6 7